文献速递创伤与烧伤复苏、休克与脓毒症重症综合管理与镇静镇痛

严重创伤患者限制性红细胞输血策略(RESTRIC)试验:集群随机、交叉、非劣效性多中心试验

The Restrictive Red Blood Cell Transfusion Strategy for Critically Injured Patients (RESTRIC) trial: a cluster-randomized, crossover, non-inferiority multicenter trial of restrictive transfusion in trauma.
PubMed 文献 · J Intensive Care · 2023-07-24
一句话结论严重创伤急性期限制性输血(目标血红蛋白7-9 g/dL)与宽松策略(10-12 g/dL)28天生存率相似,但限制性策略未达到预设非劣效界值,且输血量更低。

RESTRIC试验是在日本22家三级急诊医疗机构开展的集群随机、交叉、非劣效性多中心试验,纳入有大量出血风险的成人严重创伤患者,比较限制性(目标血红蛋白7-9 g/dL)与宽松(10-12 g/dL)输血策略对28天生存的影响。限制性组(n=216)与宽松组(n=195)28天生存率分别为92.1%和91.3%,校正OR为1.02(95%CI 0.49-2.13),未达到3%非劣效界值的统计学非劣效。限制性组输血量和血红蛋白水平更低,两组并发症发生率和无事件天数无差异。结论认为尽管非劣效未达统计学显著,但两组死亡率和并发症率相似,限制性策略输血量更低。

要点

  • 严重创伤患者急性期限制性输血(目标血红蛋白7-9 g/dL)与宽松输血(10-12 g/dL)28天生存率相似:92.1% vs 91.3%。
  • 校正OR为1.02(95%CI 0.49-2.13),未达到预设3%非劣效界值的统计学非劣效。
  • 限制性策略组输血量和血红蛋白水平均低于宽松策略组。
  • 两组并发症发生率和无事件天数无显著差异。
  • 结论认为限制性策略输血量更低,但非劣效性未获统计学证实,临床决策需结合个体情况。

适用人群与场景

  • 日本22家三级急诊医疗机构的成人严重创伤患者,有大量出血风险,抵达急诊科后立即应用研究策略。

诊断标准与关键阈值

  • 限制性输血策略目标血红蛋白水平7-9 g/dL;宽松输血策略目标血红蛋白水平10-12 g/dL。

处置流程与药物剂量

  • 机构被分配至限制性或宽松输血策略,目标血红蛋白分别为7-9 g/dL或10-12 g/dL,患者抵达急诊科后立即应用。

研究设计与关键结果

  • 研究类型:集群随机、交叉、非劣效性多中心试验,在日本22家三级急诊医疗机构开展;纳入成人严重创伤有大量出血风险患者。
  • 主要终点:28天生存率限制性组(n=216)92.1% vs 宽松组(n=195)91.3%,校正OR 1.02(95%CI 0.49-2.13),未达统计学非劣效(非劣效界值3%)。
  • 次要终点:限制性策略组输血量和血红蛋白水平低于宽松策略组;两组并发症发生率和无事件天数无差异。

证据类型、等级与局限

  • 证据类型:集群随机、交叉、非劣效性多中心试验;非劣效界值3%。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于有大量出血风险的成人严重创伤患者,急性期采用限制性输血策略(目标血红蛋白7-9 g/dL)与宽松策略相比28天生存率相似,且输血量更低,但非劣效性未达统计学显著。
  • 作者认为限制性输血策略导致更低的输血量。

指南或共识出处

  • RESTRIC试验,注册号UMIN000034405,注册日期2018年10月8日。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The efficacies of fresh frozen plasma and coagulation factor transfusion have been widely evaluated in trauma-induced coagulopathy management during the acute post-injury phase. However, the efficacy of red blood cell transfusion has not been adequately investigated in patients with severe trauma, and the optimal hemoglobin target level during the acute post-injury and resuscitation phases remains unclear. Therefore, this study aimed to examine whether a restrictive transfusion strategy was clinically non-inferior to a liberal transfusion strategy during the acute post-injury phase.

METHODS: This cluster-randomized, crossover, non-inferiority multicenter trial was conducted at 22 tertiary emergency medical institutions in Japan and included adult patients with severe trauma at risk of major bleeding. The institutions were allocated a restrictive or liberal transfusion strategy (target hemoglobin levels: 7-9 or 10-12 g/dL, respectively). The strategies were applied to patients immediately after arrival at the emergency department. The primary outcome was 28-day survival after arrival at the emergency department. Secondary outcomes included transfusion volume, complication rates, and event-free days. The non-inferiority margin was set at 3%.

RESULTS: The 28-day survival rates of patients in the restrictive (n = 216) and liberal (n = 195) strategy groups were 92.1% and 91.3%, respectively. The adjusted odds ratio for 28-day survival in the restrictive versus liberal strategy group was 1.02 (95% confidence interval: 0.49-2.13). Significant non-inferiority was not observed. Transfusion volumes and hemoglobin levels were lower in the restrictive strategy group than in the liberal strategy group. No between-group differences were noted in complication rates or event-free days.

CONCLUSIONS: Although non-inferiority of the restrictive versus liberal transfusion strategy for 28-day survival was not statistically significant, the mortality and complication rates were similar between the groups. The restrictive transfusion strategy results in a lower transfusion volume.

TRIAL REGISTRATION NUMBER: umin.ac.jp/ctr: UMIN000034405, registration date: 8 October 2018.

来源:J Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Hayakawa M, Tagami T, Kudo D, et al. The Restrictive Red Blood Cell Transfusion Strategy for Critically Injured Patients (RESTRIC) trial: a cluster-randomized, crossover, non-inferiority multicenter trial of restrictive transfusion in trauma. J Intensive Care. 2023. PMID: 37488591. doi:10.1186/s40560-023-00682-3

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。